Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Executive Summary

Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.


Related Content

Opdivo Approval Opens China I-O Doors But Pricing Key
Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO
Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers
Merck's Keytruda Keeps Nipping At Opdivo's Heels
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer
Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck
Merck's Keytruda Offers Hope And Risk In Early Breast Cancer
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts